香菊片联合注射用奥马珠单抗治疗变应性鼻炎的临床研究

Clinical Evaluation of Xiangju Tablets Combined with Omalizumab in the Treatment of Allergic Rhinitis

目的 探讨香菊片联合注射用奥马珠单抗治疗变应性鼻炎的疗效及不良反应。方法 将2021年1月至2023年12月在解放军总医院京中医疗区接受治疗的变应性鼻炎患者100例作为研究对象,按数字奇偶数法分为观察组和对照组,每组50例。对照组予以香菊片治疗,对照组在使用香菊片基础上予以注射用奥马珠单抗治疗,2组均连续治疗8周。于治疗前和治疗8周后,对患者进行鼻症状评估和生活质量评定,比较2组疗效和不良反应。结果 观察组总有效率为76.00%,显著高于对照组的42.00%(P <0.05)评分。观察组治疗8周后的鼻部症状总评分量表(TNSS)评分为4.31分,低于香菊片对照组的6.07分,变应性鼻炎生活质量问卷评分表(RQLQ)观察组为35.14分,低于对照组49.65分(P <0.05)。观察组与对照组的不良反应发生率差异无统计学意义(P> 0.05)。结论 香菊片联合奥马珠单抗治疗变应性鼻炎可提高疗效,从而改善鼻部症状。

Objective To evaluate the efficacy and side effects of Xiangju tablets combined with Omalizumab in the treatment of allergic rhinitis.Methods A total of 100 allergic rhinitis patients admitted to our hospital from January 2021 to December 2023 were enrolled.They were randomly divided into observation and control groups(50 cases per group).Patients in the control group were treated with Xiangju tablets,while those in the observation group were treated with a combination of Omalizumab and Xiangju tablets.All patients were treated for 8 weeks.Nasal symptoms and quality of life were evaluated before and after treatment.The efficacy and adverse reactions were compared between the two groups.Results The total effective rate of the observation group reached 76%,which was significantly higher than that of the control group(42%,P<0.05).After treatment,the TNSS score of the observation group was 4.31,and the RQLQ score was 35.14,both of which were significantly lower than those of the control group(P<0.05).Besides,no significant difference in adverse reactions was observed(P>0.05).Conclusion The combination of Xiangju tablets and Omalizumab demonstrated a higher therapeutic effect in allergic rhinitis,effectively improving nasal symptoms.